NewLimit
NewLimit is a biotechnology company developing epigenetic reprogramming therapies to restore youthful function in aged cells and treat age-related diseases.
Secondary Market Price
How NewLimit Measures Up
To help you manage your NewLimit equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of NewLimit's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future NewLimit Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for NewLimit's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
NewLimit is a biotechnology company developing epigenetic reprogramming therapies to treat diseases related to aging. The company's work involves using functional genomics, machine learning, and pooled perturbation screening to restore regenerative functions in aged and diseased cells. Its initial therapeutic programs are focused on the immune system and liver function. Founded in 2022 by Brian Armstrong, Jacob Kimmel, and Blake Byers, NewLimit was established to explore the possibility of reversing aging. The company has raised nearly $250 million in funding since its inception.
Looking forward, NewLimit plans to advance its first preclinical candidate, which restores youthful functions in old liver cells, toward clinical studies. The company recently announced it has discovered over 30 reprogramming payloads, launched a third therapeutic program in vascular biology, and developed AI systems that have doubled its discovery efficiency. An additional $45 million in funding brought the company's valuation cap to $1.6 billion. Future goals include expanding its therapeutic programs and continuing to use AI to increase the pace of discovery.
- Kleiner Perkins
- Dimension Capital
- Founders Fund
- Khosla Ventures
- Human Capital
- Eli Lilly & Company
- Abstract Ventures
- Duke University Management Company
- S32
- Valor Equity Partners
- Blake Byers
- Brian Armstrong
- Elad Gil
- Fred Ehrsam
- Garry Tan
- Joe Lonsdale
- John & Patrick Collison
- Joshua Kushner
- Nat Friedman
- Daniel Gross
- Co-Founder, Brian Armstrong
- Co-Founder, Blake Byers
- Co-Founder, Jacob Kimmel
- Co-Founder, Gregory Johnson
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is NewLimit worth joining?
Deciding to join a company depends on many personal and financial factors, including the potential value of its equity compensation. Tools like Prospect can help you understand what your equity might be worth by using data-driven models to project a company's future value.
What should I do with my NewLimit stock?
Managing your startup stock requires a personalized strategy based on your financial goals and tax situation. Prospect creates customized, multi-year plans for exercising options and selling shares to help you maximize your earnings and minimize taxes.
Can you sell NewLimit stock?
As NewLimit is a private company, selling stock is typically only possible during specific liquidity events like tender offers or on secondary markets. Platforms like Prospect offer tools to help you navigate these opportunities and decide how much to sell in a tax-optimal way.
How can I find the value of my NewLimit stock?
Valuing private company stock is complex, but you can get a data-driven estimate using specialized tools. Prospect uses machine learning models, trained on data similar to what VCs use, to forecast the future value of your shares.
What is NewLimit's equity worth?
The worth of your equity depends on the company's valuation and your specific grant details. To get a clear picture, Prospect can analyze your holdings and use predictive models to project the potential net value of your equity.
What is NewLimit's stock ticker symbol?
Since NewLimit is a private company, it is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are assigned only when a company undergoes an Initial Public Offering (IPO).
Can I buy or sell NewLimit stock?
Buying stock in a private company like NewLimit is generally restricted to accredited investors, while selling is limited to company-approved events like tender offers. Prospect can help employees optimize their sales during these limited liquidity windows.
What is the criteria to buy or invest in NewLimit stock?
Investing in a private startup like NewLimit is typically reserved for venture capital firms and accredited investors who participate in official financing rounds. Employees receive equity as compensation, and platforms like Prospect help them manage that stake rather than purchase it on an open market.
